Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.46USD
19 Jul 2019
Change (% chg)

$-0.07 (-2.77%)
Prev Close
$2.53
Open
$2.53
Day's High
$2.58
Day's Low
$2.45
Volume
211,401
Avg. Vol
286,205
52-wk High
$3.86
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Agenus Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Agenus Inc ::AGENUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 EARNINGS PER SHARE $0.14.Q1 REVENUE $80 MILLION.GSK'S SHINGRIX SALES CONTINUE TO GROW; PROJECTED TO BE ABOUT $1.3 BILLION IN 2019.2019 INDS ARE ON TRACK.PARTNERSHIP AND PRIVATE FINANCING DISCUSSIONS ARE UNDERWAY.  Full Article

Gilead Sciences And Agenus Enter Into Collaboration
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Agenus Inc ::GILEAD AND AGENUS ENTER INTO COLLABORATION TO DEVELOP IMMUNO-ONCOLOGY THERAPIES.AGENUS INC - AGENUS WILL RECEIVE $150 MILLION UPON CLOSING.AGENUS INC - AGREEMENT ALSO INCLUDES APPROXIMATELY $1.7 BILLION IN POTENTIAL FUTURE FEES AND MILESTONES.AGENUS INC - GILEAD WILL RECEIVE WORLDWIDE EXCLUSIVE RIGHTS TO AGEN1423, WHICH HAS AN ESTIMATED IND FILING BY YEAR-END 2018.AGENUS INC - GILEAD WILL ALSO RECEIVE EXCLUSIVE OPTION TO LICENSE TWO ADDITIONAL PROGRAMS: AGEN1223 AND AGEN2373..AGENUS INC - AGENUS HAS FILED IND FOR AGEN1223 AND HAS AN ESTIMATED IND FILING FOR AGEN2373 IN FIRST HALF OF 2019..AGENUS INC - AGENUS WILL BE RESPONSIBLE FOR DEVELOPING OPTION PROGRAMS UP TO OPTION DECISION POINTS.  Full Article

Agenus Q3 Loss Per Share $0.29
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Agenus Inc ::AGENUS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.29.Q3 REVENUE $13 MILLION.PARTNERSHIP DISCUSSIONS PROGRESSING TOWARDS CLOSURE.LEAD IDENTIFIED FOR IND FILING; PRIVATE FINANCING AND PLANS FOR IPO UNDERWAY.  Full Article

Agenus Receives Milestone Payment From Incyte
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Agenus Inc ::AGENUS RECEIVES MILESTONE PAYMENT FROM INCYTE.AGENUS INC - PAYMENT OF $5M RECEIVED FOR INITIATION OF PHASE 1 TRIAL OF LAG-3 ANTIBODY.AGENUS - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $505 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES FROM INCYTE.  Full Article

Agenus Reports Q4 Loss Per Share $0.35
Thursday, 15 Mar 2018 

March 15 (Reuters) - Agenus Inc ::AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.35.Q4 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.CASH, AND CASH EQUIVALENTS WERE $60.2 MILLION AT DECEMBER 31, 2017.QTRLY REVENUE $8.4 MILLION VERSUS $5.6 MILLION.  Full Article

Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agenus Inc ::AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS.AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE PAYMENTS.AGENUS INC - AGENUS WILL USE PART OF THE PROCEEDS TO REDEEM ITS ROYALTY BOND FROM OBERLAND, AMONG OTHERS.AGENUS INC - IN EVENT THAT CERTAIN SALES MILESTONES ARE NOT MET, AGENUS WILL OWE HCR APPROXIMATELY $26 MILLION IN 2021.  Full Article

Agenus reports Q3 loss per share $0.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Agenus Inc :Agenus reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.37.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Agenus Inc - ‍Cash, cash equivalents and short-term investments were $70.1 million at Sept 30, 2017 compared to $76.4 million as of Dec 31, 2016​.Agenus Inc - Qtrly revenue $3.4 million versus $4.4 mln‍​.  Full Article

Agenus files for mixed shelf of up to $250 million
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Agenus Inc :Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​.  Full Article

Agenus Inc Q2 loss per share $0.32
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Agenus Inc :Agenus reports second quarter 2017 financial results and provides corporate update.Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.Q2 loss per share $0.32.Cash, cash equivalents and short-term investments were $96.8 million at June 30, 2017 compared to $76.4 million as of december 31, 2016​.Qtrly ‍revenue $ 4.2 million versus $ 6.6 million.Q2 revenue view $5.0 million -- Thomson Reuters I/B/E/S.  Full Article